Myeloma News and Research

RSS

Obesity-related cancers found to be increasing among younger adults in the United States

A new study finds rates are increasing for six of 12 cancers related to obesity in younger adults in the United States, with steeper increases in progressively younger ages and successively younger generations.

4 Feb 2019

Fibrosis-targeting drugs may benefit patients with late-stage, metastatic breast cancer

A Massachusetts General Hospital (MGH) research team has found that the overgrowth of connective called fibrosis may block the effectiveness of immunotherapies against metastatic breast cancer.

29 Jan 2019

Researchers discover immune regulator that appears to dictate glioblastoma

Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation.

28 Jan 2019

Study reveals new genes and biological pathways linked to osteoarthritis

In the largest genetic study of osteoarthritis, an international team of scientists including researchers from the University of Sheffield, have uncovered 52 new genetic changes linked to the disease, which doubles the number of genetic regions associated with the disabling condition.

21 Jan 2019

Computerized method helps better protect pharma patents

Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry.

18 Jan 2019

Excess weight responsible for cancers globally finds report

According to a new report published this week, excess body weight is one of the major reasons behind cancers worldwide. The report written by scientists at the American Cancer Society (ACS) and published in the journal CA: A Cancer Journal for Clinicians shows that 3.9 percent of the cases of cancers were linked to excess body weight and this amounted to 544,300 cases in 2012.

16 Dec 2018

Research offers hope for patients with serious bone marrow cancer

Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

14 Dec 2018

Allen Institute for Immunology: A new division focused on human immune system

The Allen Institute today announced the launch of the Allen Institute for Immunology, a new division of the Institute that is dedicated to studying the human immune system.

13 Dec 2018

New method to visualize small-molecule interactions inside cells

Like people in a large company, proteins in cells constantly interact with each other to perform various jobs. To develop new disease therapies, researchers are trying to control these interactions with small-molecule drugs that cause specific proteins to associate more or less with their "coworkers."

13 Dec 2018

New technology for profiling genetic makeup of myeloma tumor cells developed

Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells - outlining how cancer cells hijack specific pathways for uncontrolled proliferation - will lead to more efficient ways to fight it.

7 Dec 2018

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.

3 Dec 2018

Vanderbilt researchers isolate antibody that can neutralize West Nile virus

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can "neutralize" the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

21 Nov 2018

Empowering the NHS through Industry Partnerships

An interview with Cara Afzal and Lee-Ann Farrell discussing the importance of industry partnerships with the NHS, and how Janssen are working to improve dementia care for Manchester and hematology services for Wales.

13 Nov 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Multiple myeloma is the second most common type of blood cancer where cancer cells accumulate in the bone marrow, crowding out healthy blood cells.

1 Nov 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Gene types that drive racial disparities in myeloma identified

Researchers at Mayo Clinic have identified three specific gene types that account for a known two-to-three-fold increase in myeloma diagnoses among African-Americans.

10 Oct 2018

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

Adaptive Biotechnologies today announced that Blood, the Journal of the American Society of Hematology, published online an analysis of patient samples from the Intergroupe Francophone du Myéloma 2009 trial.

1 Oct 2018